Ignite Creation Date:
2024-05-06 @ 3:51 PM
Last Modification Date:
2024-10-26 @ 1:58 PM
Study NCT ID:
NCT04782791
Status:
UNKNOWN
Last Update Posted:
2022-01-11
First Post:
2021-01-25
Brief Title:
Nivolumab S-1 Combined With Oxaliplatin Versus Nivolumab as Neoadjuvant Therapy in Advanced Gastric Cancer
Sponsor:
Chinese PLA General Hospital
Organization:
Chinese PLA General Hospital
Study Overview
Official Title:
A Prospective Randomized Controlled Phase II Evaluation of Nivolumab S-1 Combined With Oxaliplatin NivoSOX Versus Nivolumab Nivo as Neoadjuvant Therapy in Patients With Locally Advanced Gastric Adenocarcinoma RESONANCE-Ⅲ Study
Status:
UNKNOWN
Status Verified Date:
2022-01
Last Known Status:
NOT_YET_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The trial is a prospective randomized controlled phase Ⅱ study which will be conducted in Chinese PLA General Hospital Beijing China Patients with eligibility will enrolled and assigned into either group A for 9 weeks of nivolumab S-1 combined with oxaliplatin NivoSOX followed by D2 surgery and group B for 9 weeks of nivolumab followed by D2 surgery The primary endpoint is the safety assessed by recording adverse events and the secondary endpoints are response rate disease control rate pathological complete response rate D2 rate and R0 rate
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None